Art. -Nr.: HY-N0670

Tenacissoside H

(Synonyms: Tenacissimoside C)

1 Cited Publications

Kundenbewertung

Based on 1 publication(s) in Google Scholar

Tenacissoside H (Tenacissimoside C) is a compound found in Caulis Marsdeniae Tenacissimae. Tenacissoside H shows anti-inflammation, anti-tumor and neuroprotective effects. Tenacissoside H inhibits PI3K/Akt and NF-κB signaling pathway. Tenacissoside H inhibits cancer cells proliferation, S phase arrest, and inhibits tumor growyh in mice. Tenacissoside H promotes neurological recovery of ischemia-reperfusion injury in mice by inhibiting inflammation and apoptosis. Tenacissoside H can be used for the research of cancer, inflammation and neurological diseases, such as esophageal cancer and cerebral ischemia.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.89%
CAS. Nr.: 191729-45-0
Formel: C₄₂H₆₆O₁₄
Molecular Weight:794.97

Speicherung:

4°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Tenacissoside H Chemical Structure

CAS. Nr.: 191729-45-0

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- In Vitro
- In Vivo
Chemical Information
Publications (1)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Alle PI3K Isoform-spezifische Produkte anzeigen :

Alle Akt Isoform-spezifische Produkte anzeigen :

Alle NF-κB Isoform-spezifische Produkte anzeigen :

In Vitro

Tenacissoside H (2-10 mg/mL; 24-48 h) potently inhibits human esophageal carcinoma EC9706 cell proliferation in a time- and dose-dependent manner, with IC₅₀ values of 9.81 mg/mL at 24 h and 6.45 mg/mL at 48 h^[1].
Tenacissoside H (10 mg/mL; 24 h) blocks human esophageal carcinoma EC9706 cells from entering the S phase from the G1 phase, significantly reducing the percentage of cells in the S phase to 12.82% relative to the blank control group^[1].
Tenacissoside H (10 mg/mL; 1-7 days) downregulates PI3K and NF-κB p65 mRNA expression in human esophageal carcinoma EC9706 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1]

Cell Line:

human esophageal carcinoma EC9706 cells
Concentration:

2, 4, 6, 8, 10 mg/mL
Incubation Time:

24 h; 48 h
Result:

Significantly inhibited EC9706 cell proliferation in a time- and dose-dependent manner.
Reduced cell proliferation by 52.65% at 10 mg⋅mL^-1 after 24 h incubation.
Reduced cell proliferation by 64.79% at 10 mg⋅mL^-1 after 48 h incubation.
Exhibited an IC₅₀ of 9.81 mg/mL for 24 h incubation.
Exhibited an IC₅₀ of 6.45 mg/mL for 48 h incubation.

Cell Cycle Analysis^[1]

Cell Line:

human esophageal carcinoma EC9706 cells
Concentration:

10 mg/mL
Incubation Time:

24 h
Result:

Significantly reduced the percentage of EC9706 cells in the S phase to 12.82%.

Real Time qPCR^[1]

Cell Line:

human esophageal carcinoma EC9706 cells
Concentration:

10 mg/mL
Incubation Time:

1, 3, 5, 7 day
Result:

Reduced PI3K mRNA expression over time, with significant differences relative to the blank control group at day 5 and day 7.
Decreased NF-κB p65 mRNA expression from day 3 onward, with significant differences relative to the blank control group at day 5 and day 7.

In Vivo

Tenacissoside H (100 mg/kg; i.p.; twice weekly; 14 days) produces inhibition of esophageal tumor growth in nude mice, reduces PCNA expression, and downregulates proteins in the PI3K/Akt-NF-κB signaling pathway^[1].
Tenacissoside H (20-80 mg/kg; i.p.; daily; 5 consecutive days 30 minutes before operation) dose-dependently protects male C57BL/6 mice against cerebral ischemia-reperfusion injury, with the 80 mg/kg dose producing the most significant improvements in neurological function, reduction in brain damage, and modulation of inflammatory and oxidative stress pathways via the TrkB signaling axis^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Balb/c nude mice (male and female, 6 weeks old, 18-22 g, subcutaneous inoculation of EC9706 cells)^[1]
Dosage:

100 mg/kg
Administration:

i.p.; twice weekly; 14 days
Result:

Reduced tumor volume.
Reduced PCNA positive cell ratio to 53.02%.
Downregulated PI3K, Akt, p-Akt and NF-κB protein expression.
Induced large areas of tumor necrosis.

Animal Model:

C57BL/6 (male, 22-25 g, cerebral ischemia-reperfusion injury model via middle cerebral artery occlusion thread embolization with 2h ischemia followed by reperfusion)^[2]
Dosage:

20 mg/kg; 40 mg/kg; 80 mg/kg
Administration:

i.p.; daily; 5 consecutive days
Result:

Reduced modified Neurological Severity Score (mNSS).
Reduced apoptotic cell and Caspase3-positive cells.
Reduced cerebral MDA, SOD, GSH-PX, BDNF levels.
Reduced TNF-α, IL-1β, IL-6 levels, increased IL-4, IL-10, TGF-β levels.
Reduced iNOS relative expression, increased Arg1 relative expression, reduced Iba1-positive microglia.
Increased Nrf2 relative expression, reduced p-NF-κB relative expression, increased TrkB relative expression, increased PPARγ relative expression.

Chemical Information

CAS. Nr. 191729-45-0
Appearance Solid
Molecular Weight 794.97
Formel C₄₂H₆₆O₁₄
Color White to off-white
SMILES

C[C@@]([C@@H]([C@@H](OC(C(C)CC)=O)[C@]1([H])[C@]23C)OC(C)=O)([C@@H]4C(C)=O)[C@]5(CC4)[C@@]1(CC[C@@]2([H])C[C@@H](O[C@@](O[C@H](C)[C@H]6O[C@@](O[C@H](C)[C@@H](O)[C@H]7OC)([H])[C@@H]7O)([H])C[C@H]6OC)CC3)O5
Synonyms

Tenacissimoside C
Structure Classification
- Steroids
Initial Source
- Plants
- other families
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Publications (1)

All

Sort by:

Journal Impact Factor

Clin Exp Pharmacol Physiol

Tenacissoside H promotes neurological recovery of cerebral ischaemia/reperfusion injury in mice by modulating inflammation and oxidative stress via TrkB pathway. [Abstract]

2021 May;48(5):757-769. PMID: 32799328

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (125.79 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.2579 mL

6.2895 mL

12.5791 mL

5 mM

0.2516 mL

1.2579 mL

2.5158 mL

10 mM

0.1258 mL

0.6290 mL

1.2579 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: 5 mg/mL (6.29 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (3.14 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (3.14 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (285 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Jia YS, et al. Antitumor Activity of Tenacissoside H on Esophageal Cancer through Arresting Cell Cycle and Regulating PI3K/Akt-NF-κB Transduction Cascade. Evid Based Complement Alternat Med. 2015;2015:464937. [Content Brief]

[2]. Zhang R, et al. Tenacissoside H promotes neurological recovery of cerebral ischaemia/reperfusion injury in mice by modulating inflammation and oxidative stress via TrkB pathway. Clin Exp Pharmacol Physiol. 2021 May;48(5):757-769. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.2579 mL	6.2895 mL	12.5791 mL	31.4477 mL
	5 mM	0.2516 mL	1.2579 mL	2.5158 mL	6.2895 mL
	10 mM	0.1258 mL	0.6290 mL	1.2579 mL	3.1448 mL
	15 mM	0.0839 mL	0.4193 mL	0.8386 mL	2.0965 mL
	20 mM	0.0629 mL	0.3145 mL	0.6290 mL	1.5724 mL
	25 mM	0.0503 mL	0.2516 mL	0.5032 mL	1.2579 mL
	30 mM	0.0419 mL	0.2097 mL	0.4193 mL	1.0483 mL
	40 mM	0.0314 mL	0.1572 mL	0.3145 mL	0.7862 mL
	50 mM	0.0252 mL	0.1258 mL	0.2516 mL	0.6290 mL
	60 mM	0.0210 mL	0.1048 mL	0.2097 mL	0.5241 mL
	80 mM	0.0157 mL	0.0786 mL	0.1572 mL	0.3931 mL
	100 mM	0.0126 mL	0.0629 mL	0.1258 mL	0.3145 mL

Tenacissoside H

1 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Tenacissoside H

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

NF-κB Signaling Compound Library

PI3K/Akt/mTOR Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Anti-Cancer Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Covalent Screening Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Oxygen Sensing Compound Library

Glycolysis Compound Library

Pyroptosis Compound Library

Cytoskeleton Compound Library

Glutamine Metabolism Compound Library

Traditional Chinese Medicine Active Compound Library

Neuroprotective Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Glucose Metabolism Compound Library

Mechanoreceptors Compound Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Cancer Natural Product Library

Antidepressant Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Pain-Related Compound Library

Membrane Protein-targeted Compound Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Covalent Screening Library Plus

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Anti-Brain Cancer Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Anti-Rheumatic Arthritis Compound Library

Natural Product Diversity Scaffold Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Tenacissoside H

Alle PI3K Isoform-spezifische Produkte anzeigen

Alle Akt Isoform-spezifische Produkte anzeigen

Alle NF-κB Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (1)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Tenacissoside H Related Classifications